French pharmaceutical company Servier and US biopharmaceutical company Day One Biopharmaceuticals Inc (Nasdaq:DAWN) on Friday announced a definitive agreement for Servier to acquire Day One for USD21.50 per share in cash, representing a total equity value of approximately USD2.5bn.

Day One is focused on developing and commercialising targeted therapies for people of all ages with life-threatening diseases.

This will to reinforce Servier's position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. It strengthens Servier's portfolio and expands its oncology pipeline with programmes ranging from early stage to phase 3.

Subject to customary closing conditions, the acquisition is expected to be completed in the second quarter of 2026.